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ABSTRACT
DEVELOPMENT OF BLENDED POLYMERIC FIBERS TO ALTER
THE RELEASE OF PEPTIDE TARGETING PORPHYROMONAS
GINGIVALIS
Sonali Sapare
$SULO, 2018
Periodontitis is a chronic inflammatory disease that infects the tissues of the
periodontium. It is estimated that 47.2% or 67.2 million American adults
suffer from mild, moderate and severe periodontitis. Globally, 30-50% of the
adult population is afflicted with periodontal disease, making it one of the
most prevalent infectious diseases in the world. Therapeutics targeting P.
gingivalis may be effective to alter periodontitis progression. However, the
current treatment modalities that target critical pathogens to maintain hostbiofilm homeostasis are limited, urging the development of specifically
targeted therapeutics to limit P. gingivalis recolonization of the oral cavity
after periodontal treatment and healing. We previously identified a peptide
(BAR) that inhibits the formation of P. gingivalis-S. gordonii biofilms;
however, formulations that effectively deliver the peptide within the oral
cavity are lacking. Polymeric electrospun fibers (EFs) offer a new platform
to deliver high localized concentrations of the peptide (BAR) for prolonged
periods, to disrupt established biofilms and enhance BAR effectiveness. The
v

objective of this study was to determine if electrospun fibers (EFs) that
encapsulate the BAR peptide, function as a sustained-release drug delivery
vehicle for application in the oral cavity. A variety of polymer formulations
were electrospun using a uniaxial electrospinning approach. Polymers
including poly(lactic-co-glycolic acid) (PLGA) or methoxy-poly(ethylene
glycol) (mPEG-PLGA), polycaprolactone (PCL), and poly(L-lactic acid)
PLLA, were synthesized alone or blended in a 40:60, 20:80 and 10:90 w/w
ratio with a hydrophilic polymer, polyethylene oxide (PEO), to increase BAR
release over 24 hr. To determine the total loading of BAR in EFs, the fibers
were dissolved in DMSO, and the amount of BAR encapsulated was
compared to a known standard of fluorescently-labeled BAR (F-BAR). The
sustained-release of F-BAR from fibers was determined by comparing the
supernatant from a variety of release time points to a known standard of FBAR. PLGA, mPEG-PLGA, PCL and PLLA EFs demonstrated
encapsulation efficiencies of 68%, 94% 60% and 46% respectively, while
exhibiting minimal release of BAR (9.5%, 7%, 1.4% and 1.5%) within 24 hr.
Blended polymeric fibers comprised of PLGA:PEO, PCL:PEO, and
PLLA:PEO with 40:60, 20:80 and 10:90 w/w ratios were fabricated to
enhance release. All polymer blends incorporated high concentrations of
BAR peptide, and increasing ratios of PEO significantly enhanced BAR
release within 24 hr. The most promising 10:90 PLGA:PEO, PCL:PEO, and
PLLA:PEO formulations provided 95%, 50% and 75% BAR release at 4 hr.
vŝ
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CHAPTER 1
INTRODUCTION

Periodontal diseases are highly prevalent and can affect up to 90% of the
worldwide population. Gingivitis, the mildest form of periodontal disease, is
caused by the bacterial biofilm (dental plaque) that accumulates on teeth
adjacent to the gingiva (gums) (Pihlstrom, Michalowicz, & Johnson, 2005).
The colonization of bacteria in the supragingival area initiates an
inflammatory response (Brogden & Guthmiller, 2002; Dickinson et al.,
2011) and gingivitis, if left untreated, can lead to a more severe form of
periodontal disease characterized by clinical attachment loss, termed
periodontitis (Heijl et al., 1976). Periodontitis is a chronic, irreversible
inflammatory disease, during which the chronic infiltrate of immune cells
induces destruction of connective tissue, vascular proliferation and alveolar
bone destruction (Pihlstrom, Michalowicz & Johnson, 2005). Periodontitis is
second only to dental caries as a cause of tooth loss among adults in
developed countries (Gautam et al., 2011). 30-50% of the global adult
population suffers from periodontal disease making it one of the most
prevalent infectious diseases in the world. It is estimated that 47.2% or 67.2
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million American adults suffer from mild, moderate and severe periodontitis
(P.I Eke et al., 2012). Severe disease (subgingival pocket depths > 6mm)
occurs in 9% of U.S. adults (Adeyemi et al, 2015) and 11.2% of adults
worldwide (Eke, P., et al. 2012, Kassebaum et al, 2014). This correlates to
annual expenditures for the treatment and prevention of periodontal disease
in excess of 14 billion dollars (Eke, P., et al. 2012). Other studies have also
demonstrated that mild forms of periodontitis affect 75% of adults in the
United States and more severe forms affect 20 to 30% of adults (Dhadse et
al, 2010). Periodontal diseases are also proven to be risk factors for various
systemic diseases such as bacteremia, infective endocarditis, cardiovascular
disease, prosthetic device infection, diabetes mellitus, respiratory diseases,
rheumatoid arthritis and adverse pregnancy outcomes (Kim et al, 2006,
Scannapieco et al, 2013, Kaur et al 2014).

Dental plaque biofilm formation
A biofilm is an organized aggregate of microorganisms living within an
extracellular polymeric matrix that they produce and irreversibly attach to
fetish or living surface which will not remove unless rinse quickly (Hurlow
et al., 2015). The National Institutes of Health (NIH) revealed that among all
microbial and chronic infections, 65% and 80%, respectively, are associated
with biofilm formation (Jamal et al., 2018). Microbial biofilms are known to
cause a number of infectious diseases in humans, a few of which include
2

tonsillitis, dental disease, urinary tract infections and endocarditis. The oral
cavity is a dynamic environment and from a biofilm-formation standpoint,
the oral cavity is a propitious environment that allows for the growth of a
diverse array of microorganisms (Gibbons, 1989). In periodontal disease, the
accumulation of biofilm around the gingival margins provokes an
inflammatory response by the host. This involves an increased flow of
Gingival Crevicular Fluid (GCF) which not only introduces components of
the host response but also many molecules that can act as potential nutrients
for some of the minor components of the normal resident subgingival
microbiota (Wade, 2013). A small sample of dental plaque contains, on
average, between 12 and 27 species (Aas, Paster, Stokes, Olsen, & Dewhirst,
2005) hence dental plaque is a classic example of multispecies biofilm. The
formation of dental plaque involves several phases within seconds of tooth
eruption or after tooth cleaning (Diaz et al., 2006). Hence, understanding the
growth, progression and arrangement of plaque alongside the etiology will
aid in the development of novel therapies to treat and cure periodontitis
(Marsh, 1994).

3

Development of Dental plaque
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Figure 1. Biofilm development

The development of oral bioﬁlms depends on interactions between bacterial
cell-surface adhesins and host receptors. Interactions between different
species of bacteria, and between bacteria and the host, are central to the
development of oral bioﬁlm (Jakubovics & Kolenbrander, 2010). The key
stages in the development of a biofilm as shown in figure 1 are: first, pellicle
formation; second, adhesion of a microorganism to a surface and individual
colonization and organization of cells; third, secretion of extra cellular
polymeric substances (EPSs) and maturation into a three-dimensional
structure; and finally, dissemination of progeny biofilm cells (Seneviratne,
Zhang, & Samaranayake, 2011).

4

When the bacterial and host products come in contact with a clean tooth
surface, the negatively charged hydroxyapatite tooth surface absorbs it and
forms a thin layer of conditioning film called the acquired pellicle
(Armstrong et al, 1968). In the supragingival areas, this layer is covered by
positively-charged molecules such as salivary glycoproteins, statherin,
histatin, proline rich proteins, alpha-amylase, bacterial components like
glucosyltransferases (GTFs), glucan, and by-products from gingival
crevicular fluid in the subgingival areas (M. Hannig & Joiner, 2006). Acidic
phosphoproteins and proline-rich proteins that aid in colonization of bacteria
on to the tooth surfaces mediate the initial interaction between the pellicle
and the bacteria. In addition, other environmental cues can influence biofilm
formation including low pH, changes in osmolarity, and oxygen. The early
plaque forming bacteria or the initial colonizers are generally Gram-positive
cocci, which primarily comprise streptococcal species. (Marsh, 1994, 2006).

Adhesion of bacteria to the salivary pellicle represents the second step in the
colonization of enamel surfaces in the mouth. Oral streptococci such as
Streptococcus sanguinis, Streptococcus oralis, and Streptococcus mitis have
been shown to be the major primary colonizers, constituting 60–80% of
dental plaque within 4 to 8 hr (Diaz et al., 2006). They initially make nonspecific, reversible bonds like hydrogen bonds, hydrophobic interactions,
calcium bridges, van der Waals forces, acid-base interactions and
5

electrostatic interactions with the molecules in the acquired pellicle (C.
Hannig & Hannig, 2009; Marsh, 2005).

The main physical surface

attachment structures of bacteria are fimbriae and fibrils (Donlan, 2002). The
pellicle provides a sticky base to support further assemblage of
microorganisms (Lindh et al, 2014).

Dental plaque biofilm will continue to grow and expand by the multiplication
of the primary colonizers and co-aggregation and co-adhesion of secondary
colonizers. Primary colonizers are mostly aerobic or facultative aerobes
which reduce oxygen, allowing the anaerobic bacteria such as Actinomyces
species,

Fusobacterium

nucleatum,

Prevotella

intermedia,

and

Capnocytophagia species to enter the biofilm community (Seneviratne et al.,
2011). Co-aggregation is driven by specific receptor-ligand interactions that
allow new bacterial colonizers to adhere to the previously attached cells
(Grenier, 1992). The fundamental mechanism of aggregation is
polysaccharide

recognition

between

bacteria.

The

polysaccharide

recognition sites vary from one paired bacterial recognition to another paired
bacterial recognition, because one bacterial cell has several different
receptors which are complementary to different adhesions belonging to other
bacterial species (R. Huang, Li, & Gregory, 2011)
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As multiplication of bacteria occurs, discrete colonies of microorganisms are
formed. These microcolonies secrete extracellular polymeric substances
(EPS), and get embedded in it, thus providing a physical scaffold for the
biofilm. A mature biofilm community is formed as the microcolonies
embedded in EPS become linked together in an organized manner
(Seneviratne et al., 2011). The mature biofilm is also comprised of fluid filled
channels interspersed in the microcolonies, which provide nutrients and
oxygen required for bacterial growth. The final stage of biofilm development
is the detachment of cells from the biofilm colony and their dispersal into the
environment, which can be active or passive.
Active dispersal refers to mechanisms that are initiated by the bacteria
themselves, which includes modes like seeding dispersal, referring to the
rapid release of a large number of single cells or small clusters of cells from
hollow cavities that form inside the biofilm colony (Boles, Thoendel, &
Singh, 2005). Passive dispersal refers to biofilm cell detachment that is
mediated by external forces such as fluid shear or abrasion (Lawrence,
Scharf, Packroff, & Neu, 2002). Modes like erosion, which refers to the
continuous release of single cells or small clusters of cells from a biofilm,
and sloughing, referring to the sudden detachment of large portions of the
biofilm, can be either active or passive processes (Lappin-Scott & Bass,
2001; Marshall, 1988).

7

Etiology of Periodontitis
The complex multifactorial etiology of Periodontitis includes genetic
predisposition along with state of systemic health of the host and
environmental factors. Several other risk factors including diet, stress, and
smoking can be involved. At the microbial level, Porphyromonas gingivalis,
Tannerella forsythia, and Treponema denticola are considered as
‘periodontopathogens’, and have been classified as ‘red’ complex oral
bacteria that have are present in the pathogenic dental plaque and have
strong association with periodontitis (Darveau, Hajishengallis, & Curtis,
2012; Griffen et al., 2012; Socransky, Haffajee, Cugini, Smith, & Kent,
1998).
The role of plaque bacteria in diseased individuals can be explained by two
main hypotheses. The “non-specific plaque” hypothesis proposed that plaque
is a conglomerate of multiple microorganisms and that no specific bacteria
is responsible for the progression of periodontitis (Rosier, De Jager, Zaura,
& Krom, 2014). In view of this, mechanical therapy for plaque removal was
considered the best way to curb the disease. Contrary to this, the “specific
plaque hypothesis” proposed by Loesche purports that out of a diverse
microbial community in the oral cavity, only specific microorganisms
belonging to the ‘red’ complex are involved in the etiology of periodontitis
(Loesche, 1992). While, Porphyromonas gingivalis, Tannerella forsythia,
and Treponema denticola have strongly been identified with periodontitis, it
8

does not sufficiently elucidate the presence of pathogenic bacteria in healthy
hosts or the absence of it in diseased individuals (G. Hajishengallis &
Lamont, 2012). A more recent “keystone pathogen hypothesis” shows P.
gingivalis, even in low levels, can play a significant role in changing the
microflora from a symbiotic microbiota to a dysbiotic state, leading to
disruption of the host-microbe homeostasis (George Hajishengallis,
Darveau, & Curtis, 2012). Moreover, the recently described Polymicrobial
Symbiosis and Dysbiosis (PSD) model highlights the importance of other
microorganisms outside the ‘red’ complex capable in causing dysbiosis (G.
Hajishengallis & Lamont, 2014). Altogether, a better understanding of the
complex interactions between the microbes, host and its immunity can help
discern the etiology.

P. gingivalis and its interaction with Streptococcus gordonii
As a Gram-negative anaerobic microorganism, P. gingivalis plays a pivotal
role in periodontitis (Socransky et al., 1998). P. gingivalis has been
extensively studied, with studies by Hajishengalis et al,2012 recognizing it
as a keystone pathogen in mice and its relative ease of cultivation and genetic
modification compared to the other species (Darveau et al., 2012). Prior to
its colonization in the anaerobic environment of the subgingival pocket, it
interacts with the initial colonizer Streptococcus gordonii, a Gram-positive
commensal (Marsh, 1994). Development of biofilm occurs subsequent to the
9

initial adherence of P. gingivalis and S. gordonii deposited on the salivary
pellicle (Kolenbrander & London, 1993). The ability of P. gingivalis to
adhere, grow and retain in different areas is through adhesins including
fimbriae, hemagglutinins and proteinases (Lamont & Jenkinson, 2000). The
commensal species S. gordonii also provides an attachment substrate for
biofilm establishment by P. gingivalis (Park, Y. et al., 2005).

To limit and inhibit biofilm formation, these distinct adhesion mechanisms
can be targeted by therapeutic agents to curtail periodontal disease (Carlo
Amorin Daep, DeAnna M. James, Richard J. Lamont, & Donald R. Demuth,
2006). S. gordonii expresses the antigen I/II proteins, which are
multifunctional adhesins, and contribute to the initiation and development of
the oral biofilm (Demuth & Irvine, 2002). The SspA and SspB polypeptides,
members of the antigen I/II, adhere to the minor fimbrial antigen (Mfa) of P.
gingivalis. A previous study by (Brooks, Demuth, Gil, & Lamont, 1997)
showed the region defined by amino acid residues 1167 to 1250 of the SspB
polypeptide sequence is essential for adherence to P. gingivalis. Further
studies demonstrated that a protein determinant comprised of amino acids
1167 to 1193 designated as BAR (SspB Adherence Region) was sufficient to
interact with P. gingivalis (Demuth, Irvine, Costerton, Cook, & Lamont,
2001). A synthetic peptide comprised of this sequence potently inhibited the
protein-to-protein interactions between P. gingivalis and S. gordonii. But
10

asacchrolytic bacteria like P. gingivalis utilizes amino acids as their energy
sources making it highly proteolytic in nature. This makes the BAR peptide
susceptible to degradation. Study by Daep, et al. showed the inclusion of the
BAR’s receptor Mfa protein into P. gingivalis cell extracts can prevent the
BAR peptide’s degradation. This suggests the affinity of BAR for Mfa1 is
greater than for the proteases secreted by P. gingivalis. This overcomes the
problem of BAR’s susceptibility to degradation and hence can be utilized as
a potential therapeutic agent as it inhibits P. gingivalis adherence to
streptococci in the presence of proteolytic enzymes (Daep, Novak, Lamont,
& Demuth, 2010). In vitro experiments confirmed BAR inhibition of the
resultant formation of biofilms (IC50 = 1.3µM) (C. A. Daep, D. M. James,
R. J. Lamont, & D. R. Demuth, 2006). BAR inhibited P. gingivalis virulence
in mice when administered simultaneously with P. gingivalis infection, in
vivo (Daep, Novak, Lamont, & Demuth, 2011). Though BAR showed great
ability to inhibit and prevent the initial interaction between P. gingivalis and
S. gordonii, in vitro results exhibited weaker potency against already
established and complex biofilms. Moreover, BAR administration
demonstrated transient effects. In this study, we developed electrospun
fibers, a new delivery platform to utilize and administer BAR more
effectively against oral biofilms.

11

Nanotechnology in therapeutics
The presence of a diverse and complex microflora in the oral cavity can make
periodontitis a difficult disease to treat. Various mechanical therapies like
scaling and root planning fail to eradicate the subgingival pathogens and halt
the inflammatory cascade(Herrera, Matesanz, Bascones-Martinez, & Sanz,
2012). Systemic administration of antibiotics can result in side effects of
inadequate concentration of the drug reaching the periodontal pockets and
developing microbial resistance. Hence, local delivery systems have the
advantage of direct access to disease site bypassing the systemic route and
enhancing the efficacy of the drug.(Garg, Singh, Arora, & Murthy, 2012).
Therapeutic approaches that can target the periodontal pathogens specifically
are lacking.

Using the premise of nanotechnology, non-toxic electrospun fibers can be
fabricated to administer BAR peptide locally as they offer several
advantages. The small fiber size can help the drug be delivered to the
appropriate site (Ferrari, 2004). They have open and interconnected pores,
allowing for optimal interaction with bioactive molecules and have sufficient
binding affinity to allow release of the encapsulated drug.(Morie, Garg,
Goyal, & Rath, 2016). This project focuses on the synthesis of BARencapsulated fibers formulated via the electrospinning process.

12

Electrospinning
Electrospinning is a relatively simple, user-friendly and inexpensive process
used to fabricate fibers. It is an established technique used to produce small
diameter fibers in the range of several nanometers to micrometers. Since the
advent of using electrostatic forces to produce fibers in the 1930s (Formhals
A., 1934) it has gained popularity. Specifically, during the last 20 years it has
been employed to fabricate products for use in medical applications,
including fiber drug delivery systems and tissue engineering scaffolds.
Reasons such as being easy to handle, minimum consumption of solution,
enabling controllable fiber diameter, processing convenience, providing a
cost effective method, in parallel with process reproducibility make
electrospinning the method of choice for large scale preparation of fibers
(Thenmozhi, Dharmaraj, Kadirvelu, & Kim, 2017). The electrospinning
process converts polymeric solution into solid fibers by application of
electrical force. The many advantages of electrospinning include high
loading capacity, high encapsulation efficiency, simultaneous delivery of
diverse active agents, ease of operation, and cost-effectiveness (Wang,
Wang, Yin, & Yu, 2010). Electrospun fibers have been successfully used to
achieve different drug release profiles, such as immediate, smooth, pulsatile,
delayed, and biphasic releases (Prabaharan, Jayakumar, & Nair, 2012).
Moreover, drugs ranging from antibiotics and anticancer agents to proteins,
aptamer, DNA, and RNA have been incorporated into electrospun fibers
13

(Prabaharan et al., 2012). As shown in figure 2, the apparatus consists of a
high voltage power supply, syringe pump, syringe needle and a stainless steel
rotating mandrel as a metal collector. The main governing forces are
electromechanical and hydrodynamic forces, and its working principle is
based on when very high voltage supply applied on a polymer solution,
which induces charge within the polymer and needle. When the charge
repulsion force exceeds the surface tension, a jet is splayed from the needle
tip (referred to as a “Taylor cone”) creating droplets with very high surface
area (Goyal, Macri, Kaplan, & Kohn, 2016; Thakkar & Misra, 2017). As the
strand of solution travels to the collector, the solvent evaporates to leave
fibers.

Figure 2. Overall setup of standard horizontal electrospinning setup
including a syringe pump, polymer-drug/peptide solution, high voltage
supply, a collecting mandrel.
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In this study, we describe an approach to fabricate fibers encapsulated with
BAR peptide to provide short-term release of the peptide via uniaxial/blend
electrospinning. In uniaxial/blend electrospinning, a single nozzle syringe is
used to electrospin polymer-solvent or polymer-solution combinations into
solid porous fibers. Electrospinning is a simple approach in which watersoluble bioactive agents such as proteins, peptides, nucleic acids and also
hydrophilic/hydrophobic drugs are combined into polymer solutions
containing aqueous or organic solvents prior to electrospinning.

Figure 3. A schematic representation of blend electrospinning strategy to
formulate electrospun fibers and the expected distribution of the bioactive
molecules in the fibers.

The electrospinning process localizes biomolecules within the fibers of the
scaffolds rather than simply adsorbing them to the scaffold surface. As such,
this approach has the capability to improve sustained-release relative to
physical adsorption (Wei Ji et al., 2011). Also compared to co-axial
15

electrospinning, uniaxial spinning is relatively a simpler method with no
additional setup required to fabricate fibers. In this work, we adopt this
straightforward approach by combining the BAR peptide solubilized in an
aqueous solution (Tris-EDTA, TE) buffer and with an organic solvent blend
(dimethyl sulfoxide, DMSO/chloroform) that contains polymer solution.

Electrospun fibers
Electrospinning is a versatile method to fabricate fibers that have diameters
ranging from several nanometers to micrometers. Molecules such as proteins,
peptide, antibodies, and small molecule drugs, can be loaded within or on the
surface of fibers according to their properties. Using electrospun fibers as
drug delivery systems provides many advantages including a) high drug
loading (up to 60%) and encapsulation efficiency (up to 100%) so the drug
is released continuously for longer duration upon insertion in the body (Ball
& Woodrow, 2014), b) polymer diversity to accommodate compatibility with
physico-chemically distinct agents (Ball, Krogstad, Chaowanachan, &
Woodrow, 2012), c) easy modulation of drug release profile depending upon
the properties of polymer/polymeric blends/other materials used (Sundararaj,
Thomas, Peyyala, Dziubla, & Puleo, 2013), and d) process simplicity and
cost-effectiveness (Ball, C., & Woodrow, K. A., 2014). These fibers possess
high surface to volume ratio which would accelerate the solubility of the drug
in the aqueous solution and enhance the efficiency of the drug (Meng et al.,
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2011). With a high degree of structural perfection and resultant superior
mechanical properties (Liao, Zhang, Gao, Zhu, & Fong, 2008) electrospun
fibers have open and interconnected pores which allow for optimal
interaction with bioactive molecules, have excellent ability to deliver the
encapsulated substances to the target site and have sufficient binding affinity
to allow release of the encapsulated substance for longer duration (Morie et
al., 2016). Many studies have shown that fibers comprised of polymer blends
have a great potential for tuning drug miscibility and the resulting drugpolymer interactions could lead to different release profiles (Chou &
Woodrow, 2017).
A number of natural, synthetic, semi synthetic and biological polymers are
used.

Since

biocompatible,

biodegradable,

and

Food

and

Drug

Administration (FDA) approved polymers including PLGA (W. J. Li,
Laurencin, Caterson, Tuan, & Ko, 2002), PCL (59),PLLA (Jun, Hou,
Schaper, H. Wendorff, & Greiner, 2003) and PEO (Son, Youk, Lee, & Park,
2004) have been successfully electrospun into fibers, all the mentioned
polymers are used in this study.

17

CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS

Research Hypothesis
We hypothesize that BAR-encapsulated EFs, will provide short-term release
of therapeutically relevant concentrations of BAR. Moreover, we
hypothesize that BAR release from EFs may be modulated by changing
hydrophilic:hydrophobic polymeric fiber blend ratios. Long-term, we
believe EFs will offer a new dosage form in which to encapsulate BAR, and
will function as an effective drug delivery vehicle within the oral cavity.
Specific Aims
1. Synthesize electrospun fibers (EFs) in different formulations that
encapsulate BAR peptide.
2. Characterize the electrospun fibers (EFs) to provide release of the
peptide for up to 24 hr.
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CHAPTER 3
MATERIALS AND METHODS
Peptide Synthesis
The peptide used in this study (shown in Table 1) was synthesized by
BioSynthesis, Inc. (Lewisville, TX). It was obtained with a purity greater
than 85% and comprised residues 1167 to 1193 of the SspB (Antigen I/II)
protein sequence of S. gordonii.
Table 1 Sequence of BAR peptide.
Peptide
BAR
F-BAR

Peptide Sequence
NH2-LEAAPKKVQDLLKKANITVKGAFQLFSOH
NH2-LEAAPK-KflcVQDLLKKANITVKGAFQLFSOH

A fluorescent BAR peptide (F-BAR), synthesized by covalently attaching 6carboxyfluorescein (Flc) to the epsilon amine of the lysine residue
(underlined in Table 1), was used to determine the amount of BAR peptide
encapsulated in the electrospun fibers.
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Materials
Hydrophobic polymers including poly (lactic-co-glycolic acid) (PLGA,
50:50 lactic:glycolic acid, MW 30,000-60,000),

methoxy-poly(ethylene

glycol) (mPEG-PLGA, MW 5,000:55,000), polycaprolactone (PCL, MW
80,000), and poly(L-lactic acid) (PLLA, MW 50,000) and the hydrophilic
polymer, polyethylene oxide (PEO, MW 100,000) were purchased from
Sigma-Aldrich (St.Louis, MO, USA). Tris-EDTA (TE) buffer (pH 8.0),
phosphate buffered saline (PBS) and the organic solvents chloroform,
dimethyl sulfoxide (DMSO) and hexafluoroisopropanol (HFIP) were also
purchased from Sigma-Aldrich (St. Louis, MO, USA). All chemicals were
used directly without further purification. One milliliter plastic syringes, petri
dishes, and 20 ml scintillation vials were obtained from VWR. One ml glass
syringes were purchased from Fisher Scientific. The electrospinner was
provided courtesy of Dr. Stuart Williams at the Cardiovascular Innovative
Institute, University of Louisville.
Preparation of Polymer solutions
To prepare the hydrophobic polymer batches, PLGA, mPEG-PLGA, and
PLLA were dissolved in HFIP at a concentration of 15% (w/w). This solution
was aspirated into a 7 ml glass scintillation vial, and sealed using parafilm to
prevent evaporation of the organic solvent. Keeping the vial at eye level, the
level of the polymer solution was marked to ensure a constant volume of
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organic solvent was maintained post-incubation. The vial was placed in a
shaker at 150 rpm and incubated at 37°C overnight to solubilize the polymer.
The final volume of the polymer solution was 1 ml. The following day, BAR
peptide was dissolved in 200 µl TE buffer in a 1 ml eppendorf tube and
vortexed for 5 minutes. The BAR solution was mixed with the polymer
solvent at a concentration of 1% (w/w), followed by vortexing the
polymer/BAR solution for another 5 minutes.
To prepare blended polymers, the hydrophobic polymers PLGA, PCL and
PLLA were mixed with PEO at different ratios (40:60, 20:80, 10:90) in (w/w)
to form PLGA/PEO, PCL/PEO, and PLLA/PEO blends in chloroform at a
concentration of 15% (w/v). The blended solutions were aspirated into a 20
ml glass scintillation vial, and sealed using parafilm to prevent evaporation
of the organic solvent. Keeping the vial at eye level, the solvent meniscus
was marked to ensure a constant volume of organic solvent was maintained
post-incubation. If any solvent evaporated during incubation, the marking
was used to add fresh solvent to maintain the original solvent volume. The
vial was placed in a shaker at 150 rpm and incubated at 37°C overnight to
solubilize the polymer. The final volume of the polymer solution was 1ml.
The following day, BAR peptide was dissolved in 60 µl DMSO in a 1 ml
eppendorf tube and vortexed for 5 minutes. The BAR solution was mixed
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with the polymer solvent at a concentration of 1% (w/w), followed by
vortexing the polymer/BAR solution for another 5 minutes.
Electrospinning
The experimental set-up used for conducting electrospinning included a high
voltage power supply, syringe pump, 1ml plastic and glass syringe needle
and a 4 mm metal mandrel.
On the day of synthesis, the plexiglass case of the electrospinner was opened
to adjust the position of the collector. A 4 mm diameter stainless steel
mandrel was cleaned using sand paper to remove residue and was secured to
the collector. For the non-blended polymer solution with HFIP as the solvent
once the BAR peptide solution was mixed, 1 ml of this solution was loaded
into a 1ml plastic syringe with an 18-gauge needle tip. The syringe was held
upright for a few minutes and pushed gently to let the air bubbles out. The
syringe was then mounted on the syringe pump, setting the holder plate on
top of syringe to keep it in place. The inner diameter of the syringe pump
program was set to the internal diameter of the BD plastic syringe (4.78 mm).
The needle tip was pushed into the circular hole until the tip was roughly 1
inch into plexiglass case, and centered. The collector was adjusted such that
there was at least 10 cm distance maintained from the needle tip. The
alligator clip from the voltage source was attached to the needle tip 1 inch
away from syringe but still outside the plexiglass case. The syringe pump
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motor controls were adjusted by setting the “slide” control to 4.5 and the
“rotor” to 8. The voltage supply was set at 20 kV, and the syringe pump flow
rate was set to 0.8 ml per hour. The polymer solution was electrospun at room
temperature, under atmospheric conditions, for 1 hr 15 min, and the resulting
fine mist of solution was collected on the mandrel and allowed to dry for 15
minutes. The mandrel was removed from the collector and using a razor
blade, the fiber was cut and gently peeled off the mandrel. The fiber was
placed in a labeled petri dish and kept in desiccator for 24 hr before any
characterization (weighing) occurs, preventing residual solvent from
contributing to the fiber weight. The desiccated fibers were stored in 4°C
until use.
For the blended polymer solution with BAR peptide, 1 ml of the solution was
aspirated into a 1 ml glass syringe with a 22-guage metal blunt needle and
mounted on the automated syringe pump. The internal diameter of the
Hamilton Gastight syringe was set to 4.61 mm. A distance of 15 cm was kept
between the needle tip and the collector. The “slide” control was set to 4.5
and the “rotor” was set to 8. A voltage of 20-25 kV was applied, at a flow
rate of 0.3 ml per hr. The electrospinning processes were employed under
ambient conditions for 3 hr 20 min. The stretched and solidified polymeric
fibers were collected on a 4mm diameter stainless steel mandrel and allowed
to dry for 15 minutes. The fiber was peeled off the mandrel and placed in
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petri dish and kept in desiccator for 24 hours. After desiccation the fibers
were stored in 4°C.

Figure 4. Schematic of drug/peptide loading method within the electrospun
fiber and its proposed release kinetics.

Characterization of electrospun fibers
Functional Characterization
Encapsulation efficiency of BAR peptide in fibers.
The loading and encapsulation efficiency of the peptide in the non-blended
and blended fibers were determined by dissolving F-BAR fiber scaffolds in
DMSO. A clean razor blade was used to cut three samples of each fiber, each
weighing ~ 2-3 mg. The fiber samples were placed in a 1.5 ml eppendorf tube
and DMSO was added to create a 1mg/ml solution. The samples were
vortexed one minute, sonicated for 5 min, and left to dissolve for 1 hour in
the dark.
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A standard curve of F-BAR was obtained by making a 0.1 mg/ml F-BAR
stock solution in 1:9 DMSO:TE. The stock solution was serially diluted with
1:9 DMSO:TE to generate a concentration ranging from 0.0007 mg/ml to 0.1
mg/ml. The diluted solutions were transferred to a 96-well clear bottom
microtiter plate in triplicate, consisting of 100µl in each well.
After the incubation period, the sample solutions were vortexed and
sonicated again. The solutions were diluted 1:2, 1:5, 1:10 and 1:100 with 1:9
DMSO:TE solution, and transferred to a microtiter plate.
The diluted fiber samples and standard were measured for fluorescence at
488nm/520nm (excitation/emission) using a spectrophotometer. The amount
of BAR peptide encapsulated in fibers was determined from the known
standard curve of the BAR peptide. The loading and encapsulation efficiency
of the BAR peptide in the fiber were calculated by taking the average of the
values obtained in each dilution (1:2, 1:5, 1:10 and 1:100) of the fiber
samples.
Determination of peptide release profiles from fibers
Three samples for each of the non-blended and blended fibers each weighing
2-3 mg, were placed in clean 1.5 ml eppendorf tube. One milliliter of 1x PBS
(pH 7.4) was added to the eppendorf tube. The fiber samples were placed in
an incubator shaker at 130 rpm and 37°C for 1 hr. The supernatant was
subsequently removed and pipetted into cluster tubes arranged in a freezer
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box. To the remaining fiber in the Eppendorf tube, fresh 1x PBS was added
and incubated until the next time point. This procedure was repeated and
supernatants were obtained at 1, 2, 4, 8, 12, and 24 hr time points. The freezer
box was parafilmed and covered in aluminum foil and stored at -20°C.
A standard curve of the F-BAR was obtained and plotted by making a 1
mg/ml F-BAR stock solution with TE buffer. This stock solution was serially
diluted with TE buffer to generate a standard curve ranging from 0.03 µg/ml
to 1000 µg/ml. One hundred microliters of the standard samples were
transferred to each well of a 96-well clear bottom microtiter plate.
The supernatants at every time point of each fiber sample and the standard
were measured for fluorescence at 488nm/520nm (excitation/emission)
using a spectrophotometer. The amount of F-BAR released at each time
point was measured by comparing to a known standard of F-BAR in TE
buffer.
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CHAPTER 4
RESULTS
Functional Characterization
Previous studies have demonstrated that EFs have been effectively used to
deliver of proteins (Casper, Yamaguchi, Kiick, & Rabolt, 2005; Chew, Wen,
Yim, & Leong, 2005; Xiaoqiang Li et al., 2010; Puhl, Li, Meinel, &
Germershaus, 2014; Zeng et al., 2005). In this study we tested various
formulations of the electrospun fibers using different polymers to deliver the
BAR peptide. Initially non-blended EFs were fabricated using hydrophobic
polymers PLGA, mPEG-PLGA, PLLA with HFIP (15% w/w). PCL/HFIP
solution at 15% w/w was highly viscous and was not electrospinnable, hence
a 12% w/w of PCL:HFIP was used.
PLGA, PCL, PLLA were also blended in 40:60, 20:80, 10:90 w/w ratio with
hydrophilic polymer PEO and dissolved in chloroform (15% w/v). All
blends were theoretically loaded with 1% w/w F-BAR: polymer, such that
10 µg of F-BAR was loaded for every milligram polymer. The loading and
encapsulation efficiency were determined by assessing the fluorescence of
the dissolved polymers. The total fluorescence emitted by the dissolved EF
solution was converted to a concentration of BAR by comparing to the
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fluorescence of a known F-BAR standard (in 1:9 DMSO:TE buffer). Figure
5 shows the standard curve of free F-BAR that was used to quantify the
concentration of F-BAR in fibers.
y = 523464x
R² = 0.994
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Fluoroscence (RFU)
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Figure 5. Standard Curve for free F-BAR showing increased fluorescence
with an increase in F-BAR concentration. This graph was used to calculate
the output concentration of F-BAR for BAR-EFs. The x-axis represents the
concentration of BAR in mg/ml and the y-axis represents the fluorescence in
Relative Fluorescence Units (RFU).

Fiber
Formulation
PLGA
mPEG-PLGA
PCL
PLLA

Blend
Ratio

100:0

Overall
Polymer
Yield
(%)
59.0
52.0
51.0
42.3
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Loading
Encapsulation
BAR/Fiber
Efficiency
(µg/mg)
(%)
6.9 ± 0.1
9.4 ± 0.4
6.0 ± 0.4
4.6 ± 0.6

68.6 ± 2.5
94 ± 0.5
60 ± 4.0
46 ± 5.2

PLGA:PEO
PCL:PEO
PLLA:PEO
PLGA:PEO
PCL:PEO
PLLA:PEO
PLGA:PEO
PCL:PEO
PLLA:PEO

40:60

82.9
91.5
82.0

7.4 ± 0.5
8.6 ± 0.2
9.1 ± 0.3

74 ± 5.5
86 ± 2.4
92 ± 3.1

20:80

80.9
89.3
85.2

8.8 ± 0.2
8.9 ± 0.4
8.3 ± 0.4

88 ± 2.6
89 ± 4.0
83 ± 4.2

82.8
80
80.9

8.8 ± 0.5
6.0 ± 0.4
8.5 ± 0.3

88 ± 5.6
60 ± 4.0
85 ± 3.5

10:90

Table 2. The amount of BAR (mg) loaded in non-blended and blended
polymeric EF formulations (µg/mg). High loading capacity and
encapsulation efficiency was achieved by all fiber formulations. Nonblended EFs showed comparatively lower polymer yield than the blended
EFs.

As summarized in Table 2, the total payload for non-blended and blended
EFs ranged from 4.6 – 9.4 µg/mg and 6.0– 9.2 µg/mg, respectively,
indicating that high loading of F-BAR was achieved in all fiber formulations.
The amount of polymer incorporated into the electrospun fiber scaffold,
calculated as the overall polymer yield, ranged from 40-60% for the nonblended formula, while the blended fibers achieved higher polymer yields (
80-90%).
BAR release from BAR encapsulated EFs
To determine the release profiles of the fiber formulations, aliquots of BARencapsulated EFs were incubated in PBS at 37°C. Fluorescence of the
29

collected supernatant was measured at 1, 2, 4, 8, 12 and 24 hr. Triplicate
fluorescence readings at each time point were compared to a known standard
of the F-BAR in PBS. Figure 6 shows the cumulative release of BAR from
non-blended EFs at each time point over a 24 hr duration. PLGA and mPEGPLGA illustrates a slow release of 9.5% and 7% respectively at 24 hr. PCL
and PLLA fibers showed much less release of BAR for the same duration,
with hydrophobic-only fibers demonstrating minimal release relative to the
PEO-blended EFs. Figure 7 shows the release of F-BAR from PLGA:PEO,
PCL:PEO and PLLA:PEO blended fibers with different blend ratios (40:60,
80:20, 90:10). The hydrophobic fibers comprised of PLGA, mPEG-PLGA,
PCL and PLLA only, released minimal concentrations of BAR within 24 hr,
relative to PEO-blended fibers. Fibers comprised of 10:90 PLGA:PEO
released 8.25 µg/mg, corresponding to 93% of the encapsulated F-BAR
within the first 2 hr., and the highest among all the formulations. PLLA:PEO
and PCL:PEO 10:90 fibers released 65% and 45% of F-BAR, respectively,
within 2 hr. For the remainder of the time points, there was significant
reduction in the release of BAR. For the 20:80 blended formulations, the
PLGA:PEO fibers showed maximum release of 88%, compared to
PLLA:PEO and PCL:PEO at 58% and 25%, respectively, after 2 hr. Similar
trends in BAR release were observed for the 40:60 formulations with
PLGA:PEO exhibiting the maximum release of 78%, with PLLA:PEO at
45% and PCL:PEO at 17% after 2 hr.
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Figure 6. The cumulative release of F-BAR from 1% w/w F-BAR nonblended (100:0) PLGA, mPEG, PCL and PLLA fibers. The cumulative
release is reported as (A) µg F-BAR per mg of fiber, and (B) percent of total
loaded F-BAR. PLGA and mPEG-PLGA showed the greatest release of
encapsulated BAR among the non-blended formulations at 24 hr.
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Figure 7. The cumulative release of F-BAR from 1% w/w F-BAR blended
PLGA:PEO, PCL:PEO and PLLA:PEO fibers (A) 40:60, (B) 20:80, and
(C) 10:90. The cumulative release is reported as both µg F-BAR per mg of
fiber on the left axis, and as the percent of total loaded F-BAR on the right
axis.
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Figure 8. The cumulative release of F-BAR from the hydrophobic nonblended and PEO-blended formulations as a function of hydrophobic
polymer type (PLGA, PCL, or PLLA) and PEO ratio in each blend. The
release of encapsulated BAR increases with an increase in PEO fraction.
PLGA and PEO blends exhibit the most significant and rapid F-BAR release,
relative to PLLA and PCL blends. For all polymer types, the 10:90 blends
show the greatest peptide release as compared to 20:80 and 40:60
formulations at any given time point. PLGA:PEO (10:90) fibers provide the
greatest release among all formulations.
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Figure 8 shows the importance of the PEO ratio in the each hydrophobic fiber
type, with the 10:90 formulation showing maximum release for each
hydrophobic blend. The 40:60 PLGA:PEO, PLLA:PEO and PCL:PEO
released the least BAR (78%, 45% and 17% respectively) within the first 2
hours. The release trends for the polymer blends of different ratios were
similar, with PLGA blends achieving the highest BAR release, followed by
PLLA and PCL.
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CHAPTER 5
DISCUSSION

Periodontal disease is one of the most widespread oral diseases among the
adult population worldwide, resulting in degradation of the supporting
tissues of the teeth, thereby producing aesthetic and functional problems for
the patient. A key feature of this inflammatory disease is dependent on the
complex microbiome residing in the oral cavity. With a complex,
polymicrobial etiology, it was shown that ‘red complex’, gram-negative
anaerobic bacteria like Porphyromonas gingivalis, Treponema denticola,
Tannerella forsythia, and Filifactor alocis were some of the species
present in the pathogenic dental plaque and strongly associated with
disease (Griffen et al., 2012; Socransky et al., 1998). Formation of deep
periodontal pockets, and the persistence of subgingival plaque caused by
adhesion and colonization of bacteria via contact dependent signaling
(Donlan, 2002) stimulate a series of inflammatory reactions (Bao et al.,
2014).
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Porphyromonas gingivalis, being a prominent component of the oral
microbiome and a successful colonizer of the oral epithelium (Yilmaz, 2008),
has been suggested to function as a keystone pathogen, as it facilitates a
change in both the amount and composition of the normal oral microbiota
and creates dysbiosis between the host and dental plaque (Darveau et al.,
2012). Before it resides in the subgingival pockets as an obligate anaerobe,
its initial colonization occurs with oral commensals in the aerobic
supragingival environment. The initial species-specific supragingival
interaction between P. gingivalis and S. gordonii is considered to initiate the
biofilm formation process (Kolenbrander & London, 1993). It is mediated by
Mfa1 of P. gingivalis and SspB polypeptide of S. gordonii (Carlo Amorin
Daep et al., 2006). Hence P. gingivalis is being targeted as a significant
organism to inhibit biofilm formation.

A synthetic analog of the SspB polypeptide designated, SspB Adhering
Region (BAR), was identified (C. A. Daep et al., 2006), providing a speciesspecific target that was successful in limiting P. gingivalis colonization both
in vitro and in vivo. While BAR was successful in limiting P. gingivalis
colonization both in vitro and in vivo, it was shown to be less effective against
well-established and complex biofilms. Previous work has revealed that
BAR potently inhibits the formation of two-species biofilms, but it is less
effective in disrupting established or more complex biofilms, requiring
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higher concentrations and prolonged exposure to be effective. The objective
of this project was to synthesize and characterize EFs as a new dosage from
alternative to deliver the bioactive molecule, BAR. Fibers as a delivery
platform to the oral cavity may protect and sustain the delivery of BAR for
oral administration, and provide a mechanism to improve the therapeutic
outcomes by increasing the localized concentration of BAR. In this work, we
hypothesized that BAR-encapsulated EFs, will provide short-term release of
therapeutically-relevant concentrations of BAR and that BAR release from
EFs may be modulated by changing polymeric fiber blend ratios.
Local drug delivery carriers in the form of films (Shifrovitch, Binderman,
Bahar, Berdicevsky, & Zilberman, 2009), strips (Friesen, Williams, Krause,
& Killoy, 2002; Leung, Jin, Yau, Sun, & Corbet, 2005), and wafers
(Bromberg et al., 2000) have been applied for periodontal disease, where the
subgingival pockets act as a natural reservoir for these drug loaded devices.
However, the methods used in the fabrication of these dosage forms include
solvent casting, melt spinning and direct milling methods. These procedures
are labor intensive, time consuming, and expensive. In contrast, the
electrospinning method provides a simple to use, time and cost efficient
process. The EFs also offer several advantages compared with other dosage
forms including the large surface-to-volume ratio for better contact of the
encapsulated bioactive molecule to the surrounding medium, small diameter
fibers for efficient drug release, ability to tailor the drug release profile,
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mechanical stability, and ease of fabrication for similar application (Su, Li,
Tan, Chen, & Xiumei, 2009).
Electrospun fibers have been used as a delivery vehicle in several biomedical
applications. Some examples of their applications include utilization as
wound dressing materials, due to their unique composition and morphology
that mimics the extracellular matrix (R. Chen J.A. Hunt, 2007). For tissue
regeneration purposes − where many polymers have been electrospun with
PCL and PLGA into fibrous membranes for Guided Tissue Regeneration in
periodontics (GTR) (Inanc, Arslan, Seker, Elcin, & Elcin, 2009; Yang, Both,
Yang, Walboomers, & Jansen, 2009) and as drug delivery vehicles for
bioactive molecules, antimicrobial agents, anti-inflammatory drugs, and
anesthetics. Studies have used human periodontal ligament (hPDL) cells
seeded on PLGA EFs (Inanc et al., 2009), in combination with PCL and PLA
to deliver doxycycline (Chaturvedi, Srivastava, Srivastava, Gupta, & Verma,
2013) and metronidazole (Reise et al., 2012), respectively. Similarly, we
hypothesized that fibers that incorporated BAR peptide may be used to
facilitate delivery and enhance the local concentration of BAR in the oral
cavity.
Moreover, research by Kim et al, indicated that blending hydrophobic with
more hydrophilic polymers increased the release of lysozyme, while
maintaining lysozyme activity. Many studies also have shown the addition
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of PEO into the protein solution can be beneficial for improving protein
stability (Casper et al., 2005; C. Li, Vepari, Jin, Kim, & Kaplan, 2006; Y. Li,
Jiang, & Zhu, 2008). Given the favorable properties of the polymers
mentioned, we successfully synthesized the electrospun fibers encapsulating
the BAR using uniaxial-blend electrospinning technique for both the nonblended and blended formulations. To demonstrate the functionality of BARincorporated fibers, we initially formulated a 1% w/w of BAR:polymer,
resulting in a theoretical loading of 10 g BAR per mg of polymer. To
achieve continuous release and the release of defined quantities of the
peptide, the polymer yield and BAR encapsulation was assessed. The initial
polymer mass, used to electrospin fibers, is required to adjust the calculation
for F-BAR incorporation in absolute amount (ug BAR/mg polymer) and %
efficiency. The unblended fibers, with HFIP as their solvent showed a much
lower polymer yield ranging between 40-60% compared to blended fibers,
suggesting that HFIP may not be the best solvent in which to synthesize
BAR-encapsulated fibers. Chloroform-based blended fibers exhibited higher
overall polymer yield in comparison, indicating chloroform as the preferred
solvent to formulate BAR encapsulated fibers.
With respect to BAR encapsulation, all the resulting EFs displayed high BAR
payload, ranging from 4.7 to 9.4 µg/mg and high encapsulation efficiency
ranging from 60-90%. To further evaluate effective fiber formulations for
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BAR, release kinetics of the non-blended and blended fibers were assessed.
The cumulative release of BAR from the fibers was expressed as µg/mg and
% total, and calculated as the concentration of the BAR in the release media
relative to the actual concentration of BAR in the fibers. The release data of
the unblended fibers revealed minimal release of 9.5%, 7%, 1.5% and 1.4%
from PLGA, mPEG-PLGA, PLLA and PCL fibers respectively over a
duration of 24 hr. The high hydrophobicity of the non-blended fibers of
PLGA, PCL and PLLA likely enables release eluent to penetrate only the
outermost layer of fibers, resulting in the rapid release of BAR only near the
fiber surface.
By modulating the hydrophobicity of the fibers with the addition of
hydrophilic PEO in ratios (40:60, 20:80 and 10:90), the release was
significantly improved. The PLGA:PEO (10:90) fibers exhibited 90%
release of BAR, the highest among all the blended and non-blended
formulations within the first 2 hr, with PLLA:PEO (10:90) exhibiting 65%
release, and PCL:PEO (10:90) releasing 45% in the same time frame.
Negligible quanities of BAR were released after 24 hr.
As the concentration of PEO increased, BAR release accelerated with 10:90
ratio of PLGA/PCL/PLLA: PEO illustrating higher cumulative BAR peptide
release percent than 20:80 and 40:60 blend fibers. Studies have shown that
by introducing hydrophilic PEO into fiber formulations, the physical and
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mechanical properties of the fiber change, in addition to providing the ability
to tune encapsulant (here, BAR) release (Evrova et al., 2016). While
hydrophobic polymers provide structural integrity to the scaffold, the PEO
makes it more porous, caused by the dissolution of PEO in solution, enabling
the release of the hydrophilic BAR peptide. In addition, hydrophilic
molecules have been shown to have more affinity and compatibility with
PEO, explaining the initial burst release presented by the blended fibers.
Among

the

hydrophobic

polymers

utilized,

PLGA

formulations

demonstrated the highest release at early time points. PLLA formulations
with different concentrations of PEO showed much better release profiles
than PCL fibers over the desired duration of 24 hr. We propose that PLGA
fibers demonstrate the highest release due to its amorphous and less
hydrophobic properties, relative to PLLA and PCL. In contrast, we propose
that PCL:PEO fibers demonstrated the least burst release due to its crystalline
and slightly more hydrophobic features.
Among the formulations, though mPEG-PLGA and PLLA:PEO (40:60)
reveals the highest encapsulation efficiency of 94% and 92%, a low release
of 7% and 55% of the encapsulated BAR at the end of 24 hrs may not be
effective formulations. Taking both encapsulation efficiency and release
properties into consideration, PLGA:PEO (10:90) is considered the most
effective formulation from this study.
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In addition to materials properties, the electrospinning process itself can
affect encapsulant location within the fibers, prompting different release
kinetics. During electrospinning, the electrical force may drive BAR, to
aggregate close to the fiber surface, due to charge repulsion (Szentivanyi,
Chakradeo, Zernetsch, & Glasmacher, 2011). This localization may also
contribute to burst release.
The fibers fabricated in this study were formulated with 1% w/w
BAR:polymer. As such, they demonstrated high encapsulation efficiency
spanning 60-90%, with burst release in the first 2 hr and minimal release
thereafter. To achieve the IC50 of BAR (4 µg/ml) at every time point over the
duration of 24 hr, loading capacity may be increased. However, previous
work has shown that using a theoretical loading higher than 1 % w/w (Kim
et al., 2004) via uniaxial blended spinning process may still result in
significant initial burst release. To overcome burst release, optimize the
release kinetics, and maintain peptide stability, techniques like emulsion
electrospinning and co-axial electrospinning may be adopted (Sebe, Szabo,
Kallai-Szabo, & Zelko, 2015) (X. Li et al., 2010).
Co-axial

electrospinning

utilizes

two

different

capillary channels

concentrically arranged to keep the protein solution and polymer solution
separate creating a core and sheath morphology. The drug is trapped within
the core, which is surrounded by a polymer shell. Several studies have shown
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sustained-release of bioactive molecules using this methodology. Moreover,
the bioactivity biological agents is also maintained since it is not incorporated
into the polymer/solvent solution prior to electrospinning (W. Ji et al., 2010).
Emulsion electrospinning adopts a similar principle, where the peptide is
dissolved in an aqueous solution, which is then added to an immiscible
polymer-solvent solution creating a water-in-oil type of emulsion. This
emulsion helps to encapsulate the aqueous agents within the core, to provide
sustained and incremental release of the encapsulant. We speculate that if the
blended polymeric fibers are synthesized using this approach,

more

prolonged administration of BAR may be achieved via sustained release
In addition to the overall electrospinning technique, particular processing
parameters have been shown to impact fiber morphology. If the distance
between the syringe tip and collector is too close, there may not be enough
time for the solvent to evaporate, promoting EF adhesion to the mandrel (Z.M. Huang, Zhang, Kotaki, & Ramakrishna, 2003). We found the distance of
15 cm between the needle and the collector to be ideal, when a voltage of 2025 kV was applied. In addition, inadequate voltages and flow rates can
promote bead formation on the electrospun fibers, resulting in unstable and
irreproducible fiber morphology (Sill & von Recum, 2008).
Future studies include plans to assess the functionality of BAR encapsulated
EFs against biofilms. Given that the more hydrophilic blended fibers released
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higher amounts of BAR over 24 hr, relative to the non-blended fibers, we
suggest testing the PLGA:PEO (10:90) fibers against in vitro biofilms.
Previous work showed free soluble BAR potently inhibits P. gingivalis-S.
gordonii biofilm formation at IC50 = 1.3µM. However, with the transient
activity observed using free BAR, the high loading and encapsulation
efficiency of the fibers as shown in the results, Table 2, in parallel with the
ability to tailor the release kinetics may enable greater efficacy against
biofilm formation and disruption.
In this work, we demonstrated the feasibility, versatility and straightforward
approach of blend electrospinning to prepare BAR encapsulated EFs that
release therapeutically-relevant concentrations of BAR. Following studies
will be focused on optimizing the release kinetics of BAR EFs and testing
their efficacy against established and complex biofilms. This will be helpful
in formulating long-term therapeutics for periodontitis as an intra-pocket
delivery system, where the fibers can be immobilized in the subgingival
pocket for a longer duration of time since it can provide a durable scaffold.
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